Highlights Innovative trophon2 for Optimized Disinfection
NATIONAL HARBOR, Md.–(BUSINESS WIRE)–#HLD—Nanosonics (ASX: NAN), a leader in infection prevention solutions, will sponsor a symposium on change management and standardization in probe reprocessing at the Society of Diagnostic Medical Sonography (SDMS) Annual Conference. The company will also highlight its proprietary automated trophon®2 complete ultrasound reprocessing system at SDMS in booth #214, Sept. 26-29, 2019.
The educational symposium, entitled “A sonographer’s guide to standardization in ultrasound reprocessing: case studies in change management,” will review two case studies where ultrasound probe reprocessing was successfully standardized, with special emphasis on challenges that arise when attempting to implement best practice guidelines and new infection prevention processes. The session will be led by Raleigh White, CRA, RT(R), MA, from Hutchinson Regional Medical Center in Kansas and Robert DeJong, RDMS, RDCS, RVT, FSDMS, FAIUM.
“Ultrasound is used in almost every healthcare setting and we must ensure that semi-critical and critical endocavitary and surface transducers are reprocessed following Federal guidelines to keep patients safe from infection,” said DeJong.
“To help ensure patient safety, it’s important for sonographers and infection preventionists to work together to standardize ultrasound probe reprocessing workflows in their department,” continued DeJong. “Yet, as with anything new, challenges can arise when expanding best practices throughout a health system. The symposium will highlight real-world case studies demonstrating how cross-department collaboration and workflow considerations are key to successfully implementing and standardizing new ultrasound probe reprocessing practices.”
Nanosonics’ trophon2 is the latest innovation in automated ultrasound probe high level disinfection (HLD). Widely considered the standard of care, trophon2 offers a complete automated reprocessing solution proven to be effective against a wide range of pathogens while helping to ensure compliance with the latest Federal guidelines.
“We’re excited to showcase our breakthrough disinfection technology at the 2019 annual SDMS conference and also host a very timely and important symposium on standardizing endocavitary and surface ultrasound probe reprocessing,” said Ken Shaw, President of North America at Nanosonics. “The adoption of trophon2 in North America continues to expand as larger institutions implement and standardize HLD. Just recently, a large pediatric teaching hospital ordered 21 trophon2 systems and a nation-wide cancer center ordered 80 systems. These recent orders, along with multiple other institutions implementing our technology, underscores the vital importance of optimized probe decontamination throughout hospitals and clinics.”
About trophon* Technology
Nanosonics’ trophon* technology’s high-frequency ultrasonic vibrations generate a sonically activated, supercharged hydrogen peroxide (H2O2) mist that inactivates drug resistant pathogens and spores that cause sexually transmitted infections (STIs) such as Gonorrhea, HIV and high-risk Human Papillomaviruses (HPV),1 as well as drug resistant bacteria including MRSA. The trophon systems are installed in more than 7,000 hospitals and facilities in North America including all of the top 100 U.S. hospitals** and it’s estimated that trophon technology is protecting over 70,000 patients daily from the risks of cross-contamination. The device is compatible for use with over 1,000 surface and endocavitary probes.
Nanosonics (ASX:NAN) is a leading medical technology company headquartered in Sydney, Australia, with its North American operations based in Indianapolis. Founded in 2001, the company is one of Australia’s largest medical technology companies and a recognized leader in its sector of the global infection control market. More information may be found at www.nanosonics.us
*trophon [trophon EPR & trophon2]
1. Ryndock E, Robison R, Meyers C. Susceptibility of HPV16 and 18 to high level disinfectants indicated for semi-critical ultrasound probes. J Med Virol. 2016;88(6):1076-80.
**US News and World Report.